HX008: a humanized PD-1 blocking antibody with potent antitumor activity and superior pharmacologic properties
Author:
Affiliation:
1. School of Pharmaceutical Science, Wuhan University, Wuhan, China
2. Department of Research & Development, HanX Biopharmaceuticals, Inc, Wuhan, China
Funder
specific grant
Publisher
Informa UK Limited
Subject
Immunology,Immunology and Allergy
Link
https://www.tandfonline.com/doi/pdf/10.1080/19420862.2020.1724751
Reference54 articles.
1. Cancer immunotherapies targeting the PD-1 signaling pathway
2. Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
3. Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
4. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death.
5. Engagement of the Pd-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation
Cited by 26 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Translate Pharmacokinetics of PD-1/PD-L1 Monoclonal Antibodies from Cynomolgus Monkey to Human: Comparison of Different Approaches;Journal of Pharmaceutical Sciences;2024-09
2. The Role of CD 47 in Lymphoma Biology and Strategies for Therapeutic Targeting;Precision Cancer Therapies vol 2 ‐ Immunologic Approaches for the Treatment of Lymphoid Malignancies ‐ From Concept to Practice;2024-02-21
3. A Photoactive Supramolecular Complex Targeting PD-L1 Reveals a Weak Correlation between Photoactivation Efficiency and Receptor Expression Levels in Non-Small-Cell Lung Cancer Tumor Models;Pharmaceutics;2023-12-14
4. Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 study;Cell Reports Medicine;2023-12
5. TO MARKET, TO MARKET–2022: MACROMOLECULAR THERAPEUTICS;Medicinal Chemistry Reviews;2023-11-16
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3